journal article Open Access Nov 30, 2016

Physiologically relevant binding affinity quantification of monoclonal antibody PF‐00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation

British Journal of Pharmacology Vol. 174 No. 1 pp. 70-81 · Wiley
View at Publisher Save 10.1111/bph.13654
Abstract
Background and PurposeA monoclonal antibody (PF‐00547659) against mucosal addressin cell adhesion molecule (MAdCAM), expressed as both soluble (sMAdCAM) and trans‐membrane (mMAdCAM) target forms, showed over 30‐fold difference in antibody‐target KD between in vitro (Biacore) and clinically derived (KD,in‐vivo) values. Back‐scattering interferometry (BSI) was applied to acquire physiologically relevant KD values which were used to establish in vitro and in vivo correlation (IVIVC).Experimental ApproachBSI was applied to obtain KD values between PF‐00547659 and recombinant human MAdCAM in buffer or CHO cells and endogenous MAdCAM in human serum or colon tissue. CHO cells and tissue were minimally processed to yield homogenate containing membrane vesicles and soluble proteins. A series of binding affinities in serum with various dilution factors was used to estimate both KD,in‐vivo and target concentrations; MAdCAM concentrations were also measured using LC–MS/MS.Key ResultsBSI measurements revealed low KD values (higher affinity) for sMAdCAM in buffer and serum, yet a 20‐fold higher KD value (lower affinity) for mMAdCAM in CHO, mMAdCAM and sMAdCAM in tissue. BSI predicted KD,in‐vivo in serum was similar to clinically derived KD,in‐vivo, and the BSI‐estimated serum sMAdCAM concentration also matched the measured concentration by LC–MS/MS.Conclusions and ImplicationsOur results successfully demonstrated that BSI measurements of physiologically relevant KD values can be used to establish IVIVC, for PF‐00547659 to MAdCAM despite the lack of correlation when using Biacore measured KD and accurately estimates endogenous target concentrations. The application of BSI would greatly enhance successful basic pharmacological research and drug development.
Topics

No keywords indexed for this article. Browse by subject →

References
50
[12]
Experimental design and analysis and their reporting: new guidance for publication in BJP

Michael J Curtis, Richard A Bond, Domenico Spina et al.

British Journal of Pharmacology 10.1111/bph.12856
[21]
Karp G (2005)
[22]
A structure‐based benchmark for protein–protein binding affinity

Panagiotis L. Kastritis, Iain H. Moal, Howook Hwang et al.

Protein Science 10.1002/pro.580
[27]
Malvern (2012)
[29]
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

Daniel Martinez Molina, Rozbeh Jafari, Marina Ignatushchenko et al.

Science 10.1126/science.1233606
[42]
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

Christopher Southan, Joanna L. Sharman, Helen E. Benson et al.

Nucleic Acids Research 10.1093/nar/gkv1037
[45]
Wienken CJ "Protein‐binding assays in biological liquids using microscale thermophoresis" Nat Commun (2010) 10.1038/ncomms1093
Related

You May Also Like